Role of Toll-like receptors in COVID-19 pathogenesis
暂无分享,去创建一个
[1] C. Jonsson,et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines , 2021, Nature Immunology.
[2] N. Rezaei,et al. Role of Toll‐like receptors in the pathogenesis of COVID‐19 , 2021, Journal of medical virology.
[3] A. Cruz,et al. Molecular and biophysical mechanisms behind the enhancement of lung surfactant function during controlled therapeutic hypothermia , 2021, Scientific reports.
[4] J. P. de Rivero Vaccari,et al. The Inflammasome in Times of COVID-19 , 2020, Frontiers in Immunology.
[5] D. Jackson,et al. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model , 2020, bioRxiv.
[6] Sarah M. Albogami,et al. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective , 2020, Saudi Pharmaceutical Journal.
[7] Xingshun Xu,et al. Reader response: Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.
[8] S. Mukherjee,et al. Targeting human TLRs to combat COVID‐19: A solution? , 2020, Journal of medical virology.
[9] Eun-Kyeong Jo,et al. COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis , 2020, bioRxiv.
[10] A. Vacca,et al. Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment , 2020, Mediators of inflammation.
[11] G. Tiram,et al. Immune-mediated approaches against COVID-19 , 2020, Nature Nanotechnology.
[12] Michael Berk,et al. Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] N. Rezaei,et al. SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences , 2020, Journal of medical virology.
[14] R. Mason. Thoughts on the alveolar phase of COVID-19 , 2020, American journal of physiology. Lung cellular and molecular physiology.
[15] Michael R Hamblin,et al. The immune system and COVID-19: Friend or foe? , 2020, Life Sciences.
[16] M. Triggiani,et al. COVID 19: a clue from innate immunity , 2020, Immunologic research.
[17] N. Rezaei,et al. COVID-19: Developing from an Outbreak to A Pandemic , 2020, Archives of Medical Research.
[18] S. Mukherjee,et al. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.
[19] P. Welling,et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. , 2020, Journal of the American Society of Nephrology : JASN.
[20] F. Rincon,et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] R. Bontrop,et al. COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males? , 2020, Immunogenetics.
[22] R. Lodato,et al. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019 , 2020, Cardiovascular Pathology.
[23] J. Benito-León,et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.
[24] Cheng Wan,et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China , 2020, Kidney International.
[25] M. Sohail,et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents , 2020, Virology journal.
[26] Dingding Shen,et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? , 2020, The Lancet Neurology.
[27] K. Hashimoto,et al. Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.
[28] Gianpaolo Ronconi,et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. , 2020 .
[29] Haibo Xu,et al. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer , 2020, Journal of Thoracic Oncology.
[30] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[31] N. Rezaei,et al. Implications of Toll-like receptors in Ebola infection , 2017, Expert opinion on therapeutic targets.
[32] T. Billiar,et al. TLR4-Upregulated IL-1β and IL-1RI Promote Alveolar Macrophage Pyroptosis and Lung Inflammation through an Autocrine Mechanism , 2016, Scientific Reports.
[33] A. Słońska,et al. Mechanisms of endocytosis utilized by viruses during infection. , 2016, Postepy higieny i medycyny doswiadczalnej.
[34] M. Katze,et al. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection , 2015, mBio.
[35] Kui Li,et al. Toll-Like Receptors in Antiviral Innate Immunity , 2013, Journal of Molecular Biology.